Pediatric Liver Transplantation-Liver Fibrosis Evaluation by Using Fibrosis Panel

Summary

Liver transplantation in children is highly successful with \>80% having 20 years survival. Most pediatric liver diseases are potentially curable with liver transplantation and it is important to establish whether children who have undergone successful transplantation can expect a normal life expectancy or whether there will be a gradual decline in liver function and eventual graft loss. The most common reasons in late graft loss in children are unexplained graft inflammation ("idiopathic" post-transplant hepatitis) and graft fibrosis. PRO-C3, a disintegrin and metalloproteinase with thrombospondin motifs-generated neo-epitope marker of type III collagen formation, has been proved to be a marker of fibrosis in patients with NAFLD. The aim of this study is to explore the role of Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA) in children received liver transplantation.

Eligibility

Inclusion Criteria:

* Male or female participant must be between 8 weeks and 18 years of age.
* Participant is a recipient of a first liver allograft from cadaveric or living donors.
* Participant is a single-organ recipient (liver only).
* Participants' parent/guardian is capable of understanding the purposes and risks of the study and must sign an informed consent for the study.

Exclusion Criteria:

* Participants older than 18 years of age
* Pregnant or breastfeeding
* Active systemic infections
* Receiving any form of solid organ retransplantation
* Multiorgan transplantation
* Multi organ failure
* Congenital sufferers from heart, lung, kidney, nervous system or blood disease
* Refused to participate the study

Conditions4

Browse More Trials